Identifying the optimal target population for treatment of type 2 diabetes mellitus using receipt data

Research for finding knowledge of the optimal treatment for patients with type 2 diabetes mellitus using RWD - Optimal treatment for patients with type 2 diabetes mellitus

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000040662

Enrollment

1400000

Registered

2020-06-30

Start date

2020-04-24

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes mellitus

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Type 2 diabetes mellitus

Exclusion criteria

Exclusion criteria: Type 1 diabetes mellitus

Design outcomes

Primary

Measure	Time frame
occurrence of efficacy, safety, treatment continuity and adherence events - HbA1c decreased to less than 7.0 - Changes in HbA1c from baseline - Severe hypoglycemia expression - Changes in hepatic and renal parameters from baseline - Switching hypoglycemic drugs or not and so on	—

Countries

Japan

Contacts

Public ContactMasaki Inaba

Astellas Pharma Inc. Planning & Administration, Development

masaki.inaba@astellas.com03-3244-4589

Outcome results